Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies.

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Chronic kidney disease (CKD) is a growing global health concern with high rates of undiagnosed cases.
• CKD significantly increases the risk of cardiovascular disease (CVD) complications, which are the leading cause of mortality in affected individuals.
• The cardiorenal syndrome highlights the intricate link between heart and kidney health, where each condition exacerbates the other.

Purpose of the Study:

• To review evidence on early detection strategies for chronic kidney disease.
• To explore real-world opportunities for slowing CKD progression through optimized cardiorenal therapy.
• To emphasize the importance of managing shared risk factors like hypertension and diabetes.

Main Methods:

• Literature review of current evidence on CKD detection and management.
• Analysis of guideline-directed medical therapy for cardiorenal conditions.
• Evaluation of emerging pharmacological treatments for CKD.

Main Results:

• Emerging medications, including SGLT2 inhibitors and MRAs, demonstrate superior efficacy in slowing CKD progression compared to traditional therapies.
• Optimizing cardiorenal guideline-directed medical therapy can significantly impact patient outcomes.
• Early detection and timely intervention are critical for improving prognosis in CKD patients.

Conclusions:

• Integrated management of cardiorenal conditions is essential for reducing mortality.
• Novel therapeutic agents offer new hope for slowing the progression of chronic kidney disease.
• Addressing undiagnosed CKD and improving access to care, especially in low-resource settings, remains a priority.